Logos Global Management LP Has $4.55 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Logos Global Management LP lowered its position in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 77.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 500,000 shares of the biotechnology company’s stock after selling 1,744,960 shares during the period. Logos Global Management LP’s holdings in Astria Therapeutics were worth $4,550,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC grew its holdings in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 2,861 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Astria Therapeutics during the first quarter valued at approximately $200,000. Hsbc Holdings PLC acquired a new position in Astria Therapeutics during the second quarter valued at approximately $171,000. Finally, American International Group Inc. grew its holdings in Astria Therapeutics by 49.4% during the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after purchasing an additional 8,122 shares during the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. TD Cowen assumed coverage on Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price target on the stock. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, Oppenheimer boosted their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS opened at $12.23 on Tuesday. The company has a market capitalization of $671.59 million, a price-to-earnings ratio of -5.27 and a beta of 0.71. The firm’s 50 day simple moving average is $11.33 and its 200 day simple moving average is $10.89. Astria Therapeutics, Inc. has a fifty-two week low of $4.26 and a fifty-two week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Equities research analysts expect that Astria Therapeutics, Inc. will post -1.66 earnings per share for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.